Patent Foramen Ovale clinical trials at University of California Health
3 in progress, 2 open to eligible people
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
open to eligible people ages 18-65
The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is: • Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO. Participants will: - Undergo the procedure to implant the P3 Occluder System, if deemed appropriate. - Visit their doctor at 1 month, 3 months, 6 months, 1 year, and 5 years after the procedure for follow up exams. - Answer a phone call from study staff at 2 years, 3 years, and 4 years after the procedure to answer a survey.
at UCLA
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
open to eligible people ages 18-70
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
at UCSF
AMPLATZER PFO Occluder Post Approval Study
Sorry, in progress, not accepting new patients
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
at UCLA UCSF
Our lead scientists for Patent Foramen Ovale research studies include Sammy Elmariah, MD.
Last updated: